Back to search

Article

Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation

2026-07-05

Abstract excerpt

<h4>Background & Aims</h4> Liver transplantation improves outcomes in hepatocellular carcinoma (HCC), yet treatment options for patients with tumor recurrence remain limited to tyrosine kinase inhibitors. Glypican-3 (GPC3)-targeted CAR T cells offer a tumor-directed immune-based therapeutic strategy, but their efficacy may be limited by post-transplant immunosuppression. We developed a CAR T cell platform combini...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
58420a6a-3ff1-5cc8-8806-a461877437e8
DOI
10.64898/2026.06.30.735569
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver TransplantationDOI 10.64898/2026.06.30.735569
Select a neighboring publication to make it the new centre.